Icatibant
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314226

CAS#: 130308-48-4

Description: Icatibant is a peptidomimetic drug consisting of ten amino acids, which is a selective and specific antagonist of bradykinin B2 receptors. It has been approved by the European Commission for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency.


Chemical Structure

img
Icatibant
CAS# 130308-48-4

Theoretical Analysis

MedKoo Cat#: 314226
Name: Icatibant
CAS#: 130308-48-4
Chemical Formula: C59H89N19O13S
Exact Mass: 1303.66079
Molecular Weight: 1304.52
Elemental Analysis: C, 54.32; H, 6.88; N, 20.40; O, 15.94; S, 2.46

Size Price Shipping out time Quantity
200mg USD 2650 2 Weeks
500mg USD 3150 2 Weeks
1g USD 3950 2 Weeks
2g USD 6950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-04. Prices are subject to change without notice.

Icatibant, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Firazyr

IUPAC/Chemical Name: D-Arginyl-L-arginyl-L-prolyl-L[(4R)-4-hydroxyprolyl]-glycyl-L[3-(2-thienyl)alanyl]-L-seryl-D-(1,2,3,4-tetrahydroisoquinolin-3-ylcarbonyl)-L[(3aS,7aS)-octahydroindol-2-ylcarbonyl]-L-arginine

InChi Key: VDCFYALYBYCEPN-JXLPZLSSSA-N

InChi Code: InChI=1S/C59H89N19O13S/c60-36(13-5-19-68-57(62)63)49(83)73-40(15-6-20-69-58(64)65)51(85)75-21-7-16-44(75)54(88)76(52(86)42-25-34(80)28-71-42)29-47(81)77(50(84)37(61)26-35-12-8-22-92-35)46(30-79)55(89)78(53(87)43-24-32-10-3-4-14-38(32)72-43)45(56(90)91)18-17-39(74-59(66)67)48(82)41-23-31-9-1-2-11-33(31)27-70-41/h1-2,8-9,11-12,22,32,34,36-46,70-72,79-80H,3-7,10,13-21,23-30,60-61H2,(H,73,83)(H,90,91)(H4,62,63,68)(H4,64,65,69)(H4,66,67,74)/t32-,34+,36+,37-,38-,39?,40-,41?,42?,43?,44-,45-,46-/m0/s1

SMILES Code: N=C(N)NC(C(C1NCC2=C(C=CC=C2)C1)=O)CC[C@@H](C(O)=O)N(C([C@H](CO)N(C(CN(C([C@H]3N(C([C@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)N)=O)=O)CCC3)=O)C(C4NC[C@H](O)C4)=O)=O)C([C@H](CC5=CC=CS5)N)=O)=O)C(C6N[C@@]7([H])CCCC[C@@]7([H])C6)=O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Safety Data Sheet (SDS):

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 1304.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Kawalec P, Holko P, Paszulewicz A, Obtułowicz K. [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results]. Pneumonol Alergol Pol. 2013;81(2):95-104. Review. Polish. PubMed PMID: 23420425.

2: Cole SW, Lundquist LM. Icatibant for the treatment of hereditary angioedema. Ann Pharmacother. 2013 Jan;47(1):49-55. doi: 10.1345/aph.1R423. Epub 2012 Dec 18. Review. PubMed PMID: 23249729.

3: Charignon D, Späth P, Martin L, Drouet C. Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother. 2012 Oct;13(15):2233-47. doi: 10.1517/14656566.2012.723692. Epub 2012 Sep 13. Review. PubMed PMID: 22970904.

4: Drake D. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. Management of adult patients with icatibant in hereditary angioedema. Emerg Med J. 2011 Aug;28(8):720-1. doi: 10.1136/emermed-2011-200396-4. Review. PubMed PMID: 21788245.

5: Bouillet L. Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol. 2011 May;7(3):267-72. doi: 10.1586/eci.11.16. Review. PubMed PMID: 21595592.

6: Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor. Prescrire Int. 2010 Nov;19(110):245-7. Review. PubMed PMID: 21284353.

7: Longhurst HJ. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag. 2010 Sep 7;6:795-802. Review. PubMed PMID: 20859548; PubMed Central PMCID: PMC2941790.

8: Gras J. Icatibant for hereditary angioedema. Drugs Today (Barc). 2009 Dec;45(12):855-64. doi: 1396674/dot.2009.45.12.1424267. Review. PubMed PMID: 20135020.

9: Cruden NL, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert Opin Pharmacother. 2008 Sep;9(13):2383-90. doi: 10.1517/14656566.9.13.2383 . Review. PubMed PMID: 18710362.

10: Icatibant: HOE 140, JE 049, JE049. Drugs R D. 2005;6(4):239-44. Review. PubMed PMID: 15991885.